Incorporating New Clinical Findings in Poly ADP-ribose polymerase (PARP) Inhibition for Ovarian Cancer

Incorporating New Clinical Findings in Poly ADP-ribose polymerase (PARP) Inhibition for Ovarian Cancer is organized by PRIME Oncology and will be held during Sep 28, 2017 - Sep 28, 2018.

The target audience for this medical event is gynecologic oncologists, medical oncologists, and other healthcare providers involved in the management of patients with advanced ovarian cancer.

Topics:
• Ovarian cancer overview
• Rationale and mechanism of action of PARP inhibitors
• Clinical trial data for PARP inhibitors in ovarian cancer
• Biomarkers and patient selection
• Ongoing trials and future directions

Conference Objectives are :

After successful completion of this educational activity, participants should be able to:
• Describe the mechanism of action of PARP inhibitors and identify predictive biomarkers of sensitivity to these agents
• Assess emerging clinical data and ongoing trials involving PARP inhibitors for patients with BRCA 1/2-mutant and BRCA 1/2-wildtype ovarian cancer

Additional details will be posted as soon as they are available.